Results 61 to 70 of about 101,548 (353)

A phase 1 study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of danuglipron (PF‐06882961), an oral small‐molecule glucagon‐like peptide‐1 receptor agonist, in Japanese adults with type 2 diabetes mellitus

open access: yesDiabetes, obesity and metabolism, 2022
This study investigated the safety, tolerability, pharmacokinetics and pharmacodynamics of danuglipron (PF‐06882961), which is a novel, oral small‐molecule glucagon‐like peptide‐1 receptor agonist, in Japanese participants with type 2 diabetes mellitus ...
Ryosuke Ono   +6 more
semanticscholar   +1 more source

Semaglutide versus Tirzepatide - comparison of both drugs in treatment of diabetes type 2 and weight reduction

open access: yesQuality in Sport
In recent years, the popularity of drugs which were firstly introduced as treatment for diabetes type 2 has surged, because of their’s significant effect of managing the body weight especially for patients that suffer for diabetes type 2.
Arkadiusz Staroń   +6 more
doaj   +1 more source

Glucagon-Like Peptide-1 Receptor Agonists for Chronic Weight Management

open access: yesAdvances in Medicine, 2023
Rates of obesity have risen over the past few decades. Subsequently, the popularity of the pharmaceutical weight-loss drug market has grown over the past few years to meet growing demand. Among the most commonly prescribed drugs for weight management, many are glucagon-like peptide-1 receptor agonists (GLP-1 agonists) which are also utilized for the ...
Magda Wojtara   +3 more
openaire   +2 more sources

Redox regulation meets metabolism: targeting PRDX2 to prevent hepatocellular carcinoma

open access: yesMolecular Oncology, EarlyView.
PRDX2 acts as a central redox hub linking metabolic dysfunction‐associated steatohepatitis (MASH) to hepatocellular carcinoma (HCC). In normal hepatocytes, PRDX2 maintains redox balance and metabolic homeostasis under oxidative stress. In contrast, during malignant transformation, PRDX2 promotes oncogenic signaling, stemness, and tumor initiation ...
Naroa Goikoetxea‐Usandizaga   +2 more
wiley   +1 more source

Glucagon-Like Peptide-1 Receptor Agonist Liraglutide Ameliorates the Development of Periodontitis

open access: yesJournal of Diabetes Research, 2020
Periodontitis is one of the diabetic complications due to its high morbidity and severity in patients with diabetes. The prevention of periodontitis is especially important in diabetic patients because the relationship between diabetes and periodontitis ...
Noritaka Sawada   +14 more
doaj   +1 more source

Novel and ultra-rare damaging variants in neuropeptide signaling are associated with disordered eating behaviors. [PDF]

open access: yesPLoS ONE, 2017
OBJECTIVE:Eating disorders develop through a combination of genetic vulnerability and environmental stress, however the genetic basis of this risk is unknown. METHODS:To understand the genetic basis of this risk, we performed whole exome sequencing on 93
Michael Lutter   +7 more
doaj   +1 more source

G-protein-coupled receptors for free fatty acids: nutritional and therapeutic targets [PDF]

open access: yes, 2014
It is becoming evident that nutrients and metabolic intermediates derived from such nutrients regulate cellular function by activating a number of cell-surface G-protein coupled receptors (GPCRs).
Brian D. Hudson   +6 more
core   +2 more sources

The photoswitchable cannabinoid azo‐HU308 enables optical control of Ca2+ dynamics in INS‐1 β‐cells via off‐target effects on TRPC channels

open access: yesFEBS Open Bio, EarlyView.
Light activation of the photoswitchable cannabinoid ligand azo‐HU308 triggers Ca2+ influx in pancreatic β‐cells through TRPC channels, independent of CB2 cannabinoid receptors. This reveals a non‐GPCR pathway for cannabinoid modulation of β‐cell Ca2+ dynamics and establishes azo‐HU308 as an optical tool to study cannabinoid signaling through TRP ...
Alexander E. G. Viray, James A. Frank
wiley   +1 more source

Tirzepatide: Does the Evidence to Date Show Potential for the Treatment of Early Stage Type 2 Diabetes?

open access: yesTherapeutics and Clinical Risk Management, 2022
Tanzila S Razzaki,* Alyson Weiner,* Alpana P Shukla Comprehensive Weight Control Center, Division of Endocrinology, Diabetes, and Metabolism Weill Cornell Medicine, New York, NY, USA*These authors contributed equally to this ...
Razzaki TS, Weiner A, Shukla AP
doaj  

Amelioration of inflammatory myopathies by glucagon‐like peptide‐1 receptor agonist via suppressing muscle fibre necroptosis

open access: yesJournal of Cachexia, Sarcopenia and Muscle, 2022
Background As glucocorticoids induce muscle atrophy during the treatment course of polymyositis (PM), novel therapeutic strategy is awaited that suppresses muscle inflammation but retains muscle strength.
Mari Kamiya   +2 more
doaj   +1 more source

Home - About - Disclaimer - Privacy